Opthea to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Business update to include masked Phase 3 patient demographics and baseline characteristics.
MELBOURNE, Australia and PRINCETON, N.J. — Opthea Limited (ASX/NASDAQ:OPT), a clinical-stage biopharmaceutical company, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for 5:15 PM PT on a Wednesday in an upcoming year and will take place in San Francisco.
Frederic Guerard, PharmD and Chief Executive Officer of Opthea, will provide a significant update during this key event. His presentation will cover business updates that include patient demographics and baseline characteristics from the pivotal Phase 3 trials of sozinibercept focused on wet age-related macular degeneration (wet AMD).
The J.P. Morgan Healthcare Conference serves as an important platform for healthcare and biotechnology companies to showcase their advancements. Opthea’s executive team is excited to attend and will be available for one-on-one meetings throughout the conference dates.
Insights into Sozinibercept Trials
The pivotal trials of sozinibercept, which include COAST and ShORe, are fully enrolled and aim to demonstrate the efficacy of this innovative therapy in conjunction with standard-of-care anti-VEGF-A treatments. The company's approach intends to deliver superior vision gains for patients suffering from wet AMD compared to existing treatments.
In these competitive trials, Opthea aims to showcase the unique benefits that sozinibercept can provide to patients, addressing unmet needs in the treatment landscape for retinal diseases.
Preserving Vision: Opthea's Commitment
Opthea is committed to developing novel therapies to treat highly prevalent and progressive retinal diseases, which include not only wet AMD but also diabetic macular edema (DME). These conditions can severely impact quality of life, making effective treatments critical.
Sozinibercept’s development has been a part of Opthea’s strategy to meet these critical needs. The company believes that through innovative research and clinical trials, they can significantly contribute to the field of ophthalmology.
Where to Find Further Updates
For those interested in following Opthea’s journey and advancements, the live webcast of the presentation will be accessible on the “Events & Presentations” section of their website. A replay of this presentation will be available for 30 days post-event, keeping stakeholders informed of the latest developments.
Additionally, interested parties can stay updated about Opthea’s programs and significant announcements by subscribing to their email updates. This proactive communication approach reflects the company’s commitment to transparency and engagement with its community.
Frequently Asked Questions
What is the primary focus of Opthea's presentation at the conference?
The presentation will highlight updates regarding sozinibercept, including patient demographics and baseline characteristics from Phase 3 trials.
What type of diseases does Opthea focus on treating?
Opthea develops therapies for retinal diseases, specifically targeting conditions like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
How can stakeholders access the presentation?
The live webcast will be available on Opthea’s website, with a replay accessible for 30 days after the event.
Who is presenting on behalf of Opthea at the conference?
Frederic Guerard, PharmD, the CEO of Opthea, will deliver the presentation at the conference.
Where can I find more information about Opthea's research?
Detailed information about Opthea’s clinical trials and research can be found on their official website.
